Midostaurin, a multikinase inhibitor with potent activity against KIT D816V, has emerged as a key therapeutic option in advanced systemic mastocytosis, including ASM, SM with an associated hematologic neoplasm, and mast cell leukemia. Here, KIT is linked to mast cell leukemia.